Placeholder

Down Syndrome – Pipeline Insights, 2015

$1250 - $4000

No. of Pages

60

Release Date

31-12-2015

Delivery Format

PDF

Geographical Coverage

Worldwide

Pricing

Enquire for discount Inquiry Before Buying

Summary
DelveInsight’s, Down Syndrome- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the Down Syndrome. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The Down Syndrome Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, Down Syndrome- Pipeline Insights, 2015 Report covers the Down Syndrome pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides Down Syndrome related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Down Syndrome.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– DelveInsight’s report provides a Down Syndrome Landscape across the globe
– The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
– Coverage of the Down Syndrome pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for Down Syndrome and also provide company profiling
– Pipeline products coverage based on various stages of development from NDA filings to discovery.
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for Down Syndrome
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Track your competitors and develop strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
– Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table of Contents
• Down Syndrome Overview
• Down Syndrome Pipeline Therapeutics
• Down Syndrome Therapeutics under Development by Companies
• Down Syndrome Late Stage Products (Filed and Phase III)
• Comparative Analysis
• Down Syndrome Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• Down Syndrome Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• Down Syndrome Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Down Syndrome – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Down Syndrome – Discontinued Products
• Down Syndrome – Dormant Products
• Companies Involved in Therapeutics Development for Down Syndrome
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Down Syndrome, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Down Syndrome Assessment by Monotherapy Products
• Down Syndrome Assessment by Combination Products
• Down Syndrome Assessment by Route of Administration
• Down Syndrome Assessment by Stage and Route of Administration
• Down Syndrome Assessment by Molecule Type
• Down Syndrome Assessment by Stage and Molecule Type
• Down Syndrome Therapeutics – Discontinued Products
• Down Syndrome Therapeutics – Dormant Products
• Products under Development by Companies, 2015
List of Figures
• Number of Products under Development for Down Syndrome, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Down Syndrome Assessment by Monotherapy Products
• Down Syndrome Assessment by Combination Products
• Down Syndrome Assessment by Route of Administration
• Down Syndrome Assessment by Stage and Route of Administration
• Down Syndrome Assessment by Molecule Type
• Down Syndrome Assessment by Stage and Molecule Type

This healthcare and pharma insights & market research report requires few ‘real-time updates’, in addition to all readily available information, which may take 48 to 72 hours (excluding weekends and public holidays) of processing and complete report delivery after placing an order.

Category

Publisher

DelveInsight